.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Deloitte
Novartis
Cantor Fitzgerald
Teva
Federal Trade Commission
Moodys
Accenture
Covington
Cerilliant

Generated: December 13, 2017

DrugPatentWatch Database Preview

DESYREL Drug Profile

« Back to Dashboard

Which patents cover Desyrel, and when can generic versions of Desyrel launch?

Desyrel is a drug marketed by Pragma Pharms Llc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

The generic ingredient in DESYREL is trazodone hydrochloride. There are thirteen drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the trazodone hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Pragma Pharms LlcDESYRELtrazodone hydrochlorideTABLET;ORAL018207-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Pragma Pharms LlcDESYRELtrazodone hydrochlorideTABLET;ORAL018207-004Nov 7, 1988DISCNYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Pragma Pharms LlcDESYRELtrazodone hydrochlorideTABLET;ORAL018207-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Pragma Pharms LlcDESYRELtrazodone hydrochlorideTABLET;ORAL018207-003Mar 25, 1985DISCNYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: DESYREL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,314,236Trazodone and trazodone hydrochloride in purified form► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DESYREL

Country Document Number Estimated Expiration
Mexico2010001094► Subscribe
Portugal2178850► Subscribe
European Patent Office2178850► Subscribe
Hong Kong1139405► Subscribe
Japan2010535170► Subscribe
Slovenia2178850► Subscribe
China101772490► Subscribe
South Korea101505522► Subscribe
Australia2008285779► Subscribe
Denmark2178850► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Dow
Farmers Insurance
QuintilesIMS
Citi
Federal Trade Commission
AstraZeneca
Merck
Argus Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot